期刊文献+

应用SELDI-TOF-MS技术分析不同中医证型肝癌血清标志物的研究 被引量:2

The application of SELDI-TOF-MS technology in analyzing different TCM syndromes of liver cancer serum markers
下载PDF
导出
摘要 目的:应用表面加强激光解析电离飞行时间质谱(SELDI-TOF-MS)检测不同中医证型肝癌患者血清蛋白质指纹图谱,筛选特异性相关血清生物学标志物。方法:应用SELDI-TOF-MS蛋白质芯片技术检测5种中医证型(气滞证、脾虚证、湿热证、血瘀证、阴虚证)肝癌患者血清,获得CM10蛋白质芯片蛋白表达图谱,用Marker Wizard软件分析差异蛋白并经数据库搜索初步鉴定。结果:应用弱阳离子交换芯片(CM10)在不同中医证型肝癌血清中检测到在不同质荷比(M/Z)差异蛋白质峰,气滞证组M/Z为4182Da、6589Da及湿热证组M/Z为5710Da的血清蛋白质峰下调,脾虚证组M/Z为5816Da、血瘀证组M/Z为4297Da、阴虚证组M/Z为6992Da的血清蛋白质峰上调,上述蛋白质含量差异均有统计学意义(P<0.01)。结论:应用SEIDI-T0F-MS可以筛选不同中医证型肝癌患者血清特异性生物标志物,检测到的差异蛋白质可能是鉴别肝癌不同中医证型的血清生物学指标。 Objective:Surface-enhanced laser desorption/inionation-time of flight-mass spectrometry(SELDI-TOF-MS) was used to study the serum proteome of hepatocellular carcinoma(HCC) with different syndrome of TCM.Methods:The serum of normal people and patients with different syndrome HCC were collected and tested by CM10 protein chip and SELDI-TOF-MS technology.The data of spectra were analyzed by bioinformatics tools and biomarker pattern discrimination software.Results:Compared with normal group,the peak intensity of M/Z 4182Da、6589Da protein of Qi stagnation syndrome,M/Z 5710Da of Damp heat syndrome were reduced significantly(P0.01),while the peak intensity of M/Z 5816Da of Spleen deficiency syndrome,M/Z 4297Da of blood stasis syndrome,M/Z 6992Da of Yin deficiency syndrome were increased(P0.01).Conclusion:These proteins might be related to HCC with different TCM syndrome,and could become candidate biomarkers for clinic differentiation of syndromes in HCC.
出处 《中医临床研究》 2012年第21期28-29,31,共3页 Clinical Journal Of Chinese Medicine
基金 福建省中医药科研重点课题(WZZZ0913)
关键词 原发性肝癌 证型 SELDI-TOF-MS 蛋白质组 Hepatocellular carcinoma Syndrome SELDI-TOF-MS Proteome
  • 相关文献

参考文献12

  • 1Parkin DM,Bray F, Ferkay J,et al.Global Cancer statistics[J].2002,CA Cancer J C1in,2005,55(2):74-108.
  • 2陈建国,宋新明.中国肝癌发病水平的估算及分析[J].中国肿瘤,2005,14(1):28-31. 被引量:93
  • 3杨秉辉,夏景林.原发性肝癌的临床诊断与分期标准[J].肿瘤防治研究,2002,29(1):83-83. 被引量:117
  • 4郑莜萸.中药新药临床研究指导原则[S].北京:中国医药科技出版社,2002.156-167.
  • 5郭振球.微观辨证学的研究现状与发展趋势[J].中医药学刊,2003,21(5):645-646. 被引量:39
  • 6Humphery-Smith I,Cordwell S,Blachstock W, et al.Proteome research:compl ementarity and limitations with respect to the RNA and DNA worlds[J]. Electrophoresis, 1997,18(8): 1217-1242.
  • 7Dove A. Proteomics:translafing genomics into products?[J].Nature Biotechnol, 1999,17(3) :233 -236.
  • 8刘喜平.蛋白质组学与中医方证研究思考[J].中医杂志,2004,45(4):247-248. 被引量:9
  • 9Engwegen JY, Gast MC, Schellens JH, et al.Clinical proteomics:searching for better tumour markers with SELDI-TOF mass spectrometry[J].Trends Pharmacol Sci,2006,27(5):251-259.
  • 10Tang N, Tomatore P, Weinberger S, et al. Current developments in SELDI affinity technology[J].Mass Spectrom Rev,2004,23:34-44.

二级参考文献20

  • 1陈建国.PooledAnalysis──流行病学研究中的一个新方法[J].中华流行病学杂志,1994,15(4):231-233. 被引量:3
  • 2陈家旭.中医证实质研究所存在的问题与对策[J].中国中医药科技,1995,2(4):35-37. 被引量:11
  • 3中华人民共和国恶性肿瘤地图集编辑委员会.中华人民共和国恶性肿瘤地图集[M].上海:中华地图学社出版,1979.1-99.
  • 4Stewart BW, Kleihues P. World Cancer Report[M].Lyon:IARC, 2003.1-351.
  • 5Ferlay J, Bray F, Pisani P, et al. Globocan 2000: Cancer incidence, mortality and prevalence worldwide.IARC CancerBase No.5[DB/CD]. Lyon: IARC, 2001.
  • 6Parkin DM, Whelan SL, Ferlay J, et al. Cancer incidence in five continents,Ⅷ. IARC Sci Publ No.155[M].Lyon:IARC, 2002.212-231.
  • 7Parkin DM, Whelan SL, Ferlay J, et al. Electronic database of cancer incidence in five continents,Ⅷ [DB/CD].Lyon: IARC, 2002.
  • 8Wang QS.Cancer registration in China [J].Asian Pacific J Cancer Prev,2001,2(S):3-8.
  • 9Thomas TK, Qian GS, Chen JG, et al. Translational strategies for cancer prevention in liver [J]. Nat Rev Cancer,2003,3(5): 321-329.
  • 10Stward BW,Kleihues P.World Cancer Report[M].Lyon:IARC,2003:1-351.

共引文献368

同被引文献37

  • 1官士珍,付玉荣,伊正君,李猛,裴景亮,高昆山.以hsa-miR-491-3p为靶标的反义寡核苷酸对NCI-H446细胞生物学特性的影响[J].中国癌症杂志,2011,21(3):171-176. 被引量:3
  • 2Lu CH,Ge F,Zhi L,et al.Detection of abundant proteins in multiple myeloma cells by proteomics[J].J Proteomics Bioinform,2010,3(1):5-9.
  • 3Wang QT,Li YZ,Liang YF,et al.Construction of a multiple myeloma diagnostic model by magnetic bead-based MALDI-TOF mass spectrometry of serum and pattern recognition software[J].Anat Rec,2009,292(4):604-610.
  • 4Svachova H,Pour L,Sana J,et al.Stem cell marker nestin is expressed in plasma cells of multiple myeloma patients[J].Leuk Res,2011,35(8):1008-1013.
  • 5Felicetti F,Parolini I,Bottero L,et al.Caveolin-1 tumor-promoting role in human melanoma[J].Int J Cancer,2009,125(7):1514-1522.
  • 6NiansongQ,Takayuki U,Nobuko K,et al.Prognostic significance of tumor/stromal caveolin-1 expression in breast cancer patients[J].Cancer Sci,2011,102(8):1590-1596.
  • 7Podar K,Shringarpure R,Tai Y,et al.Caveolin-1 is required for vascular endothelial growth factor-triggered multiple myeloma cell migration and is targeted by bortezomib[J].Cancer Res,2004,64(20):7500-7506.
  • 8Lund T,Abildgaard N,Andersen T,et al.Multiple myeloma:changes in serum C-terminal teopeptide of collagen type Ⅰ and bone-specific alkaline phosphatase can be used in daily practice to detect imminent osteolysis[J].Eur J Hematol,2010,84(5):412-420.
  • 9Kowalska M,Druzd-Sitek AZ,Kotowicz B,et al.Procollagen Ⅰ amino-terminal propeptide as a potential marker for multiple myeloma[J].Clin Biochem,2010,43(6):604-608.
  • 10Terpos E,Dimopoulos MA,Shrivastava V,et al.High levels of serum TIMP-1 correlate with advanced disease and predict for poor survival in patirents with multiple myeloma treated with novel agents[J].Leuk Res,2010,34(3):399-402.

引证文献2

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部